期刊文献+

伊布利特对老年心房颤动患者转复的疗效和安全性观察及护理 被引量:2

Observation of the efect and nursing of ibutilide for conversion of atrial fibrillation in old patients
下载PDF
导出
摘要 目的观察伊布利特对老年心房颤动患者转复的有效性和安全性,总结围转复期的护理经验,以便更安全的应用伊布利特。方法将90例心房颤动老年患者随机分为2组,其中伊布利特组54例给予静脉注射伊布利特进行心律转复;普罗帕酮组36例给予静脉应用普罗帕酮进行心律转复,严密观察转复过程中的心电图、血压情况,比较2组药物对不同病程心房颤动患者转复成功率的影响,并观察转复过程中的不良反应。结果伊布利特组对不同病程组患者转复的成功率显著高于普罗帕酮组,差异有统计学意义(P<0.05)。2组不良反应均较轻微。结论对于老年心房颤动患者,伊布利特是相对安全有效的转复药物之一,严格把握适应证和禁忌证并严密观察能够有效减少不良事件的发生。 Objective To evaluate the efficacy and safety of ibutilide for conversion of atrial fibrillation in old patients and find out nursing measures for coping with the disease safely use of ibutilide. Methods 90 cases elderly patients with atrial fibrillation were randomly divided into two groups, which ibutilide group of 54 cases patients were given intravenous ibutilide cardioversion for rhythm ; Propafenone group of 36 cases patients were given intravenous propafenone eardioversion for rhythm, closely observed the process of re-turn the ECG,blood pressure, compared drugs on the different course of patients with atrial fibrillation eardioversion success rate of two groups,and observed the process of re-turn of adverse reactions. Results Cardioversion success rate of patients with different duration in ibutilide group were significantly higher than those in propafenone group, the difference were statistically significant ( P 〈 0.05 ). Adverse reactions of two groups were mild. Conclusion For elderly patients with atrial fibrillation,ibutilide is relatively safe and effective transfer of complex drugs. To master the indication and contraindicatin strictlv and observe exactlv can effectlv decrease the bad events.
出处 《临床合理用药杂志》 2011年第21期10-11,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 伊布利特 心房颤动 护理 老年人 Ibutilide Atrial fibrillation Nursing Elderly
  • 相关文献

参考文献7

  • 1Stambler BS,Wood MA,Ellenbogen KA,et al.Ibutilide Repeat Dose Study Investigators.Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation[J].Circulation,1996,94(7):1613-1621.
  • 2Nair M,George LK,Koshy SK.Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation[J].J Am Board Fam Med,2011,24(1):86-92.
  • 3Kafkas NV,Patsilinakos SP,Mertzanos GA,et al.Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter[J].Int J Cardiol,2007,118(3):321-325.
  • 4张海澄,郭继鸿,方全,郑亚安,孙跃民,朱文青,万征,郭静萱,葛均波,韩少梅.静脉注射伊布利特与普罗帕酮转复心房颤动和扑动的多中心研究[J].中华医学杂志,2005,85(12):798-801. 被引量:43
  • 5Fuster V,Ryden LE,Cannom DS,et al.2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation:a report of the American college of cardiology Foundation/American heart association task force on practice guidelines developed in partnership with the European society of cardiology and in collaboration with the European heart rhythm association and the heart rhythm society[J].Am Coll Cardiol,2011,57(11):101-198.
  • 6Camm AJ,Kirchhof P,Lip GY,et al.Guidelines for the management of atrial fibrillation:the task force for the management of atrial fibrillation of the european society of cardiology(ESC)[J].Eur Heart J,2010,31(19):2369-2429.
  • 7王英.伊布利特转复老年心房颤动/心房扑动的观察与护理[J].现代中西医结合杂志,2010,19(14):1792-1793. 被引量:2

二级参考文献13

  • 1张海澄,郭继鸿,方全,郑亚安,孙跃民,朱文青,万征,郭静萱,葛均波,韩少梅.静脉注射伊布利特与普罗帕酮转复心房颤动和扑动的多中心研究[J].中华医学杂志,2005,85(12):798-801. 被引量:43
  • 2Li Y,Tian L,Huang Y,et al.Pharmacokinetic and pharmacodynamic properties of a single intravenous dose of ibutilide fumarate:a phase I,randomized,open-label,increasing-dose study in healthy Chinese men[J].Clin Ther,2007,29(9):1957-1960.
  • 3Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 g-uidelines for the management of patients with atrial fibrillation:a report of the american college of cardiology/american heart association task force on practice guideline and the european society of cardiology committee for practice guideline[J].Circulation,2006,114(7):700-752.
  • 4Miller MR, McNamara RL, Segal JB,et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a Meta analysis of clinical trials. J Fam Pract,2000,49:1033-1046.
  • 5Cropp Js, Antal EG, Talbert RL,et al. Ibutilide: a new class Ⅲ antiarrhythmic agent. Parmarcotherapy, 1997,17:1-9.
  • 6Lych JR, Baskin EP, Nutt EM, et al, Comparision of binding to rapidly activating delayed rectifier K channel, Ikr and effects on myocardial refractoriness for class Ⅲ antiarrythmic agents. J Cardiovasc Pharmacol, 1995,25:336-340.
  • 7Naccarelli GV, Lee KS, Gibson JK, et al. Electrophysiology and pharmacology of Ibutilide. Am J Cardiol,1996,78(8A): 12-16.
  • 8Baskin EP , Lynch JJ Jr. Differential atrial versus ventricular activities of class Ⅲ potassium channel blockers. Pharmacol Exp Ther, 1998,285:135-142.
  • 9Ellenbogen KA, Stambler BS, Wood MA, et al . Efficacy of intravenous Ibutilide for rapid termination of atrial fibrillation and atril flutter: a dose-response study. J Am Coll Cardiol, 1996, 28: 130-136.
  • 10Gowdw RM, Punukollu G, Khan LA, et al. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety. Am J Ther, 2003,10: 259-263.

共引文献42

同被引文献13

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部